GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

BRISBANE, CALIFORNIA, May 15, 2024 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2024 financial results for the period ended March 31, 2024.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks